New drug cocktail shows promise for rare, aggressive breast cancer
NCT ID NCT03202316
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 34 times
Summary
This study tests two drug combinations for people with inflammatory breast cancer that has come back or spread. One group gets three drugs (atezolizumab, cobimetinib, and eribulin) and the other gets two (atezolizumab and eribulin). The goal is to see how well these treatments shrink tumors. About 37 adults with this rare, fast-growing cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BREAST INFLAMMATORY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.